US Patent 7,785,627: Scope, Claim Architecture, and US Landscape for the Metformin Immediate-Release Pioglitazone Once-Daily Tablet
US Drug Patent 7,785,627 claims a once-daily, oral tablet that uses a multi-part architecture to stage drug release: (1) a metformin core protected by a semipermeable membrane that has internal passageways; (2) a primary seal coat that rapidly disperses in water and has no actives; and (3) an immediate-release pioglitazone coating applied over the primary seal coat, with defined dissolution and exposure windows for both APIs. The claims also narrow processing (solvent application for the pioglitazone coat) and narrow composition (specific polymer classes and specific ranges for the metformin core and pioglitazone coating components).
What does Claim 1 actually cover? (Core claim scope)
Claim 1 is the dominant independent claim and is defined by four coupled elements that must all be present:
1) Once-daily oral tablet with a staged, layered release system
The tablet has:
- (a) Core
- (b) Primary seal coat over the semipermeable membrane
- (c) Immediate release pioglitazone coating over the primary seal coat
- (d) Optional aesthetic coating
2) Metformin core: compressed mixture with constrained excipient ranges
Core (a) consists of a compressed mixture of:
- (I) 50–98% metformin hydrochloride
- (II) 0.1–40% binding agent
- (III) 0–20% absorption enhancer
- (IV) 0–5% lubricant
Core (a) may further include:
- a secondary seal coat surrounding the compressed mixture
- a semipermeable membrane that is integral to release control
3) Semipermeable membrane: polymer class + passageways + internal release
The semipermeable membrane consists essentially of:
- (I) 50–99% polymer selected from a defined cellulose-derived group
(includes ethylcellulose; cellulose esters/diesters/triesters/ethers; cellulose ester-ether; cellulose acylate/diacylate/triacylate; and specific acetates and propionates/butyrates)
- (II) 0–40% flux enhancer
- (III) 0–25% plasticizer
The membrane has:
- at least one passageway formed therein for release of metformin
4) Primary seal coat: no actives and rapid water dispersibility
Primary seal coat (b) is:
- applied to the semipermeable membrane
- does not contain an active pharmaceutical ingredient
- rapidly disperses or dissolves in water
5) Immediate-release pioglitazone coating: defined composition and rapid dissolution
Pioglitazone coating (c) is an “immediate release” coating applied to the primary seal coat (b) and contains (by tablet total weight):
- (i) 0.1–20% pioglitazone hydrochloride
- (ii) 0.1–30% binder
- (iii) 0–25% pore former
- (iv) 0–20% surfactant
Processing linkage in Claim 1:
- the immediate-release pioglitazone coating is applied to primary seal coat (b) which is applied to the semipermeable membrane on the core
6) In vivo and in vitro performance targets: Tmax staging + dissolution profiles
Claim 1 locks the composition architecture to performance metrics.
Metformin exposure (in vivo):
Metformin dissolution in USP Type 2
- 75 rpm in 900 mL simulated intestinal fluid, 37 °C
- 0–15% released after 2 hours
- 20–40% released after 4 hours
- 45–90% released after 8 hours
- at least 60% released after 12 hours
Pioglitazone exposure (in vivo):
Pioglitazone dissolution in USP Type 1
- 100 rpm in pH 2.0 HCl-0.3M KCl buffer
- at least 79% released after 20 minutes
- at least 95% released after 30 minutes
Practical meaning of Claim 1’s coupling
The claim is not just a “dual drug combination.” It is a device-like release system: the metformin is delayed and staged by a semipermeable membrane with passageways; the pioglitazone is essentially front-loaded by an immediate-release topcoat; and the primary seal coat is required to be actives-free and fast-dispersing to enable the pioglitazone to release without altering metformin membrane function.
How does Claim 2 narrow the manufacturing route for the pioglitazone coat?
Claim 2 depends on Claim 1 and adds:
- the immediate-release pioglitazone coating is applied using a solvent mixture of water and an organic solvent.
This narrows the method of application (coating formulation/process), which matters for design-around because it creates a pathway where a substitute process could fall outside Claim 2 while still meeting most Claim 1 elements (unless the substitute still meets Claim 1’s base structural and performance limitations).
What tighter composition boundaries appear in Claims 3–5?
Claim 3: core composition tightening (preferred sub-range)
Claim 3 further limits the compressed mixture of the core to:
- 75–95% metformin hydrochloride
- 3–15% binding agent
- 2–10% absorption enhancer
- 0.5–1% lubricant
This is narrower than Claim 1 and acts as a fallback that can catch products within this specific composition regime even if other applicants move toward different excipient ratios.
Claim 4 and Claim 5: specific polymer selection
Both Claim 4 and Claim 5 state:
- polymer of the semipermeable membrane is cellulose acetate
Because Claim 4 and Claim 5 are duplicates as written, the legal effect is the same limitation applied to Claim 1 through the dependent claim.
For landscape analysis, this makes the “cellulose acetate only” subset a clean capture point: products using other cellulose derivatives (still within the cellulose class in Claim 1) might avoid Claims 4/5 while still falling under Claim 1.
Where is the claim vulnerable to design-around? (scope pressure points)
Claim 1’s breadth is substantial, but it has clear technical pressure points. Any non-infringing competitor product must avoid at least one required limitation or performance target.
1) Remove or change the semipermeable membrane architecture
Claim 1 requires:
- a semipermeable membrane “consisting essentially of” specified cellulose-derived polymer + flux enhancer + plasticizer, and
- at least one passageway for metformin release.
Design-around levers include:
- eliminating passageways,
- changing membrane function away from a passageway-controlled release mechanism, or
- using a membrane chemistry that is outside the “selected from” cellulose group (or outside “consisting essentially of” boundaries).
2) Break the “primary seal coat” requirements
Claim 1 requires:
- actives-free primary seal coat that rapidly disperses or dissolves in water.
A competitor could target:
- a primary coat that includes an active (even if not intended as metformin/pioglitazone), or
- a coat that is not “rapidly disperses/dissolves in water” by the claim’s terms.
3) Break the pioglitazone dissolution/exposure profile
Even if the layered structure is replicated, Claim 1 requires:
- pioglitazone Tmax 1–4 hours
- USP Type 1 dissolution: >=79% at 20 minutes, >=95% at 30 minutes.
A competitor product that slows pioglitazone dissolution slightly might fall outside Claim 1 on performance metrics alone.
4) Avoid the specific “immediate release pioglitazone coating” component ranges
Claim 1 imposes:
- pioglitazone HCl 0.1–20%
- binder 0.1–30%
- pore former 0–25%
- surfactant 0–20%
If a product uses materially different composition ratios or different dose scaling that makes it outside these ranges, it can reduce infringement risk.
5) Process-based narrowing for Claim 2 only
Claim 2 can be avoided by changing solvent systems used to apply the pioglitazone coating. Even then, Claim 1 still stands unless the structural/performance limitations remain met.
How broad is Claim 1 compared with common dual-API tablet strategies?
Claim 1 is broader than a “single polymer” tablet claim because it covers a family of cellulose-derived polymers (cellulose acetates, acetates propionates/butyrates, cellulose esters/ethers, ethylcellulose, etc.). It is narrower than a generic combination claim because it requires:
- two distinct release regimes in one tablet:
- metformin delayed by semipermeable membrane with passageways
- pioglitazone immediate on top
- explicit in vivo Tmax windows for both APIs
- explicit USP dissolution windows for both APIs
In market terms, that makes the claim cover a specific delivery engineering template rather than simply “a combo pill.”
What does the dependent claim set add to freedom-to-operate? (Claim layering)
The dependent claims create a tiered net:
| Claim |
Extra limitation over Claim 1 |
Landscape effect |
| 1 |
Full layered tablet + semipermeable cellulose membrane with passageways + primary seal coat actives-free and rapid + immediate-release pioglitazone + Tmax and dissolution targets |
Broadest capture; drives infringement analysis |
| 2 |
Pioglitazone coating applied using water + organic solvent |
Narrower, process-specific; helps catch products using that solvent system |
| 3 |
Core composition sub-range (75–95% metformin HCl; 3–15% binding agent; 2–10% absorption enhancer; 0.5–1% lubricant) |
Narrows formulation; a fallback hook |
| 4 |
Semipermeable membrane polymer = cellulose acetate |
Polymer-specific capture |
| 5 |
Same as Claim 4 (duplicate) |
No new scope vs Claim 4 |
US patent landscape implications for metformin + pioglitazone fixed-dose combinations
Release-system patents vs. composition patents
Claim 1 is a formulation-delivery system claim: it regulates the interface between:
- metformin core compaction,
- semipermeable membrane polymer selection,
- presence of release passageways,
- seal-coat dissolution behavior,
- pioglitazone coat immediate dissolution behavior.
That places it in the same litigation class as patents that differentiate products on:
- membrane design and excipient selection,
- coating application method,
- in vitro/in vivo performance targets.
Design-around strategy cluster
Potential non-infringing approaches (at a scope level) center on changing at least one of these “hard requirements”:
- membrane polymer class outside the cellulose group,
- removing passageways,
- changing primary seal coat dissolution character,
- altering dissolution kinetics such that pioglitazone fails the USP Type 1 timepoint constraints,
- altering composition ranges (pioglitazone coat or metformin core).
Key Takeaways
- Claim 1 defines a staged-release platform: metformin delayed via a semipermeable cellulose-based membrane with passageways, while pioglitazone is immediate release via a dedicated top coating.
- The patent is anchored to both in vivo and in vitro performance gates: metformin Tmax 8–12 hours plus USP Type 2 release checkpoints; pioglitazone Tmax 1–4 hours plus USP Type 1 release checkpoints.
- Dependent claims create a tiered net:
- Claim 2 narrows coating solvent system (water + organic solvent).
- Claim 3 narrows metformin core excipient ranges.
- Claims 4 and 5 narrow the membrane polymer to cellulose acetate.
- In freedom-to-operate terms, the fastest infringement risk screening is to test whether a candidate product:
- uses a cellulose-derived semipermeable membrane with passageways,
- uses an actives-free, rapidly dissolving primary seal coat,
- and meets the pioglitazone dissolution/timepoint criteria while keeping metformin release in the specified window.
FAQs
1) What are the key claim limitations that most directly determine infringement?
The core layered architecture (core + semipermeable membrane with passageways + actives-free rapid primary seal coat + immediate-release pioglitazone topcoat) plus the metformin and pioglitazone Tmax and USP dissolution timepoint constraints.
2) Does the patent require cellulose acetate specifically?
No. Claim 1 covers multiple cellulose-derived polymers listed in the claim. Cellulose acetate is specifically required only in dependent Claims 4 and 5.
3) What makes the pioglitazone portion “immediate release” in the claim?
Not only the coating label, but the measured performance: Tmax 1–4 hours and dissolution in USP Type 1 (>=79% at 20 minutes and >=95% at 30 minutes in the specified medium).
4) Can a product avoid Claim 2 but still infringe Claim 1?
Yes. Claim 2 adds a specific solvent mixture (water + organic solvent) for applying the pioglitazone coating. A product can potentially avoid that process limitation while still meeting Claim 1’s structural and performance requirements.
5) Is the metformin release controlled by the membrane composition or by the passageways?
Claim 1 requires both: a membrane “consisting essentially of” specified cellulose-derived polymer plus flux enhancer and plasticizer, and at least one passageway formed therein for metformin release.
References (APA)
[1] U.S. Patent No. 7,785,627.
